The company went from hero to zero in the fight against COVID-19.Shares of Emergent BioSolutions (NYSE: EBS) fell 30% in April, according to data from S&P Global Market Intelligence, after quality-control errors at one of the company's facilities ruined millions of doses of Johnson & Johnson's COVID...

https://www.fool.com/investing/2021/05/04/why-emergent-biosolutions-stock-dropped-30-in-apri/?source=iedfolrf0000001

#fool